SCHEMBL2201914

SCHEMBL2201914

CC(C)(C)OC(=O)N1CCN(c2ncc3c(c2Cl)COC3=C2C(=O)Nc3ccc(F)cc32)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
TOP1 P11387 2/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
IDO2 Q6ZQW0 1/20 0.37
MAPT P10636 2/20 0.36
KIT P10721 2/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
RET P07949 5/20 0.36
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
GRIA1 P42261 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201910 1.00 NR1H2 (0.39) NR1H2NR1H3TOP1CCNT1CDK9
SCHEMBL2199139 0.85 CHRM1 (0.40) TOP1TDO2KITPDGFRBKDR
SCHEMBL2199144 0.85 CHRM1 (0.40) TOP1TDO2KITPDGFRBKDR
SCHEMBL2202131 0.83 LRRK2 (0.44) TOP1KITPDGFRBKDRTP53
SCHEMBL2202129 0.83 LRRK2 (0.44) TOP1KITPDGFRBKDRTP53
SCHEMBL2203113 0.69 PDGFRB (0.45) TOP1KITPDGFRBKDR
SCHEMBL2200668 0.68 KDR (0.45) TOP1KITPDGFRBKDRRET
SCHEMBL12225675 0.66 ALDH1A1 (0.39) TOP1KITPDGFRBKDRLMNA
SCHEMBL30893588 0.65 GPR119 (0.52) NR1H2NR1H3MAPTKITLMNA
SCHEMBL2420435 0.65 GPR119 (0.52) NR1H2NR1H3MAPTKITLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455535-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2013-06-04 US disclosed
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors ALLERGAN, INC. (US) 2011-10-20 US disclosed
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US disclosed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors REN, JAK2, ABL1 NR1H2 592/4885NR1H3 705/4885TOP1 2633/4885
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS REN, JAK2, ABL1 NR1H2 592/4885NR1H3 705/4885TOP1 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.